Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06547840 | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha | recruiting | Phase 1 | 45 | Epsilogen LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 |
| clinicaltrials |
| NCT04588402 | Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India(HPV-Vac-S) | recruiting | — | 5,500 | International Agency for Research on CancerOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05752448 | Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)(POSTCARE-O) | recruiting | N/A | 120 | Baylor College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04475640 | Cancer Genetic Testing in Ethnic Populations | recruiting | N/A | 1,800 | Mayo ClinicOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07290894 | Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01(MITO VULVA-01) | recruiting | Phase 2 | 80 | National Cancer Institute, NaplesOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer(EndoMAP) | recruiting | Phase 1 / Phase 2 | 148 | Alliance Foundation Trials, LLC.OTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT06290193 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04093388 | Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama(Pap) | recruiting | N/A | 250 | University of Alabama at BirminghamOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06969833 | Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma(BCB-OVAIRE) | recruiting | N/A | 371 | Centre Oscar LambretOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07256236 | SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 89 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH(2026ColECFerSp) | recruiting | Phase 2 | 30 | Wang JianliuOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05142033 | Avera Cancer Sequencing and Analytics Protocol (ASAP)(ASAP) | recruiting | — | 25,000 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05286034 | Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme(AppDate-You) | recruiting | N/A | 3,000 | International Agency for Research on CancerOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06366490 | Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer | recruiting | Phase 1 | 8 | PhotonPharma, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06692335 | HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids | recruiting | N/A | 112 | Chinese University of Hong KongOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06836869 | Modified Tumor-free Techniques Operation to Cervical Cancer(MOTTO) | recruiting | N/A | 524 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495384 | Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study | recruiting | N/A | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495397 | Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) | recruiting | N/A | 98 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05112991 | Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | recruiting | Phase 2 | 108 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05427487 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | recruiting | Phase 1 | 70 | ImmVirx Pty LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05990426 | Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy(FAST) | recruiting | N/A | 30 | Northwestern UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491081 | EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection | recruiting | N/A | 1,500 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04226313 | Self-sampling for Non-attenders to Cervical Cancer Screening(KOPRETINA) | recruiting | N/A | 15,000 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03010124 | Prognostic and Predictive Biomarkers in Ovarian Cancers(OvBIOMark) | recruiting | N/A | 350 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05610735 | Combination Therapy for Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 72 | Sham Sunder KakarOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | recruiting | N/A | 800 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480785 | TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients | recruiting | N/A | 780 | Zhejiang UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480954 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)(DUAL-OV-CAR-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT03785574 | Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule | recruiting | N/A | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06483048 | MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | recruiting | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07469709 | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks(PRO-ACTIVE) | recruiting | — | 850 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | recruiting | Phase 2 | 148 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03968406 | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04712851 | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07460180 | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer(PROOV) | recruiting | Phase 1 / Phase 2 | 55 | The Netherlands Cancer InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06142760 | MR-guidance in Chemoradiotherapy for Cervical Cancer(AIM-C1) | recruiting | N/A | 40 | Juergen DebusOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 6, 2026source: clinicaltrials